Technology
Health
Biotechnology

Celldex

$2.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.43%) Today
+$0.12 (5.08%) As of 5:56 PM EDT after-hours

Why Robinhood?

You can buy or sell Celldex and other stocks, options, ETFs, and crypto commission-free!

About CLDX

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Read More Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Employees
137
Headquarters
Hampton, New Jersey
Founded
1983
Market Cap
30.19M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
96.12K
High Today
$2.48
Low Today
$2.31
Open Price
$2.33
Volume
199.54K
52 Week High
$11.62
52 Week Low
$2.31

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
US
North America

CLDX Earnings

-$1.40
-$0.95
-$0.49
-$0.04
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.